Date: 2018-01-23
Type of information: Private placement
Company: Ultragenyx Pharmaceutical (USA - CA)
Investors:
Amount: $250 million
Funding type: private placement
Planned used:
Others:
- • On January 23, 2018, Ultragenyx Pharmaceutical, a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, announced the pricing of its underwritten public offering of 4,385,965 shares of its common stock at a price to the public of $57.00 per share, resulting in gross proceeds of $250 million before underwriting discounts. In addition, the company has granted the underwriters of the offering an option for a period of 30 days to purchase up to an additional 657,895 shares of the company's common stock at the public offering price, less the underwriting discount. The offering is expected to close on or about January 26, 2018, subject to satisfaction of customary closing conditions.
- • On January 22, 2018, Ultragenyx Pharmaceutical announced that it has commenced an underwritten public offering of up to $175,000,000 of shares of its common stock. In addition, the company is expected to grant the underwriters of the offering an option for a period of 30 days to purchase up to an additional $26,250,000 of shares of common stock at the public offering price, less the underwriting discount. J.P. Morgan Securities LLC, BofA Merrill Lynch, Goldman Sachs & Co. LLC and Cowen are acting as joint book-running managers for the offering.
Therapeutic area: Rare diseases - Genetic diseases
Is general: Yes
